

Principle

The following tables display the antimicrobial agents included in our laboratory's routine Antimicrobial Susceptibility Testing platforms. Each table lists the antimicrobials (grouped by class or subclass) routinely used to determine in vitro susceptibility of bacterial pathogens isolated from human specimens. Results obtained from antimicrobial susceptibility testing are selectively reported based on recommendations from the Clinical and Laboratory Standards Institute (CLSI), Lab Medical Directors, Infectious Disease, St. Luke's Antimicrobial Stewardship Committee, and AST panel manufacturer guidelines.

Please note

- *In vitro susceptibility does not guarantee clinical response. The decision to treat with a particular agent should not be based solely on the antimicrobial susceptibility result.*
- *Aminoglycosides (non-synergistic use), clindamycin, and trimethoprim-sulfamethoxazole are not clinically effective in the treatment of Enterococcus spp.*
- *The following antimicrobial agents are not considered effective for treating CSF infections caused by the organisms listed in these tables, and will not be reported on CSF specimens: (1) Agents administered by oral route only, (2) 1st and 2nd generation cephalosporins, (3) Clindamycin, (4) Macrolides, (5) Tetracyclines, and (6) Fluoroquinolones.*

Table 1. Antimicrobials routinely tested against Gram Positive Aerobic Bacteria

Gram Positive Aerobe (<i>Staphylococcus</i> and <i>Enterococcus</i> spp.) Antimicrobial Reporting Chart	β-lactams																				Lipopeptide			Glycopeptide			Oxazolidinone			Ansamycin			Streptogramin			Fluoroquinolones			Folate Pathway		
	Penicillins (Labile)		Penicillin (Stable)		Cephalosporins			β-lactam combos			Carbapenems			Macrolides			Aminoglycosides			Lipopeptide			Glycopeptide			Oxazolidinone			Ansamycin			Streptogramin			Fluoroquinolones			Folate Pathway			
	Penicillin	Ampicillin	Oxacillin	Cephalothin	Cefazolin	Cefotaxime	Ceftriaxone	Cefepime	Ceftaroline	Amoxicillin/K clavulanate	Ampicillin/ Sulbactam	Piperacillin/ Tazobactam	Imipenem	Meropenem	Aztreomycin	Erythromycin	Clindamycin	Gentamicin	Synergy Screen	Streptomycin	Synergy Screen	Gentamicin	Daptomycin ¹	Vancomycin	Linezolid ²	Rifampin	Syn	Ciprofloxacin	Levofloxacin	Nitrofurantoin	Tetracycline	Trimethoprim/ Sulfamethoxaz	Antagonist								
Abbreviation	P	Am	Ox	Cf	Cfz	Cft	Cax	Cpe	Cpt	Aug	A/S	P/T	Imp	Mer	Azi	E	Cd	GmS	SmS	Gm	Dap	Va	Lzd	Rif	Syn	Cp	Lvx	Fd	T/S												
<i>Staphylococcus aureus</i>		X	X	X	X	X	X	X	X	X	X	X	X	SYS	SYS	SYS					X	X	X	X	X	SYS	X	X	UR	X											
<i>Other Staphylococcus spp.</i>		X	X	X	X	X				X	X	X	X	SYS	SYS	SYS					X	X	X	X	X	X	X	UR	X	X											
<i>Enterococcus</i> spp.	X	X																		X	X	X	X	X	X	X	UR	UR	UR												
β-hemolytic streptococcus & <i>S. pneumoniae</i> (SPN)	X					X	X	X		SPN				SPN	X	X										X	SPN	SPN													

X—routinely reported when appropriate (limitations noted by superscripts) SYS—Reported on Systemic (non-urine) sources only UR—Reported on Urine sources only SPN—*S. pneumoniae* only

1—Daptomycin reported when Vancomycin inactive (except on respiratory tract isolates)

2—Linezolid reported when Vancomycin or Daptomycin inactive



Antibiotic Panels 2022

St. Luke's Microbiology

Effective Date: 1/21/2021

SOP # 100

Version 1

Page 2 of 3

Table 2. Antimicrobials Routinely Tested against Gram Negative Aerobic Bacilli

Gram Negative Aerobe Antimicrobial Reporting Chart	Antimicrobial Testing Panel																											
	Beta-Lactams		β-lactam combos										Carbapenems		Aminoglycosides				Fluoroquinolones				Tetracyclines			Folate Pathway Ant		
	Monobactam	Penicillin	Cephamycin	1 st gen.	2 nd gen.	Cephalosporins (generation)			3 rd gen.	4 th gen.	5 th gen.	β-lactam combos																
	Aztreonam	Ampicillin	Cefoxitin	Cefazolin	Cefuroxime	Ceftaxime	Ceftriaxone	Ceftazidime	Cefepime	Ceftaroline	Aug	A/S	CZA	C/T	MEV	P/T	Etp	Mer	To	Gm	Ak	Cp	Lvx	Mxf	Te	Min	Fd	T/S
Abbreviation	Azt	Am	Cfx	Cfz	Crm	Cft	Cax	Caz	Cpe	Cpt	Aug	A/S	CZA	C/T	MEV	P/T	Etp	Mer	To	Gm	Ak	Cp	Lvx	Mxf	Te	Min	Fd	T/S
Enterobacteriales	X	X	X	X	X	X	X	X			X	X	RQ1	RQ2	RQ3	X	X	X	X	X	X	X	X	SYS	X	X	UR	X
<i>Pseudomonas aeruginosa</i>	X							X	X				RQ1	RQ2		X		X	X	X	X	X	X	X				
<i>Acinetobacter</i> spp.						X	X	X	X			X				X		X	X	X	X	X	X		UR	X		X
<i>Stenotrophomonas maltophilia</i>								X																X				X

RQ1 – Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam agents are only reported by request, and only on *P. aeruginosa* and specific species of Enterobacteriales

RQ2 - Performance of ceftolozane/tazobactam is unknown for *P. aeruginosa*. C/T is not active against Enterobacteriales spp. that produce metallo-beta lactamases and serine carbapenemases.

SYS: Only Systemic therapy reported.

URN: Only Urine therapy reported.

RQ3 –reported only by request.

Footnote: Shaded boxes denote drug/organism combinations not acceptable for reporting based on manufacturer/FDA guidelines.



915 East First Street
Duluth, MN 55805

Antibiotic Panels 2022

St. Luke's Microbiology

Effective Date: 1/21/2021

SOP # 100

Version 1

Page 3 of 3

References

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100* (ISBN 978-1-68440-066-9 [Print]; ISBN 978-68440-067-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2020.

Microscan Therapy Guide for Use with LabPro Software v5.0 (and later). Technical Document 9020-8076, Rev. AB. Beckman Coulter, Inc. 250 S. Kraemer Blvd., Brea, CA 92821, USA, 2020.

Written by Jennifer Berglund, M (ASCP) on January 21st, 2021.

Revision History:

Resubmitted for approval July, 2022

APPROVAL SIGNATURES

Prepared January 2021

Reviewed and Approved by:

Department Medical Director Jon Steinhauer, MD	Jon Steinhauer, MD 11/02/2022
Laboratory Medical Director: Steven J. Eastep, MD	Steven J. Eastep, MD 7/19/2022
St. Luke's Microbiology Technical Specialist Jennifer Berglund	Jennifer Berglund, 7/19/2022
Laboratory Administrative Director Jennifer Viergutz	Jennifer Viergutz 7/19/22
Laboratory Operations Manager Paige Andersen	Paige Andersen 7/19/22
P&T Committee Chair Harmony Tyner MD	Harmony Tyner 7/27/22